| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Biosimilar Pharmaceuticals | 27 | 2023 | 29 | 12.090 |
Why?
|
| Arthritis, Rheumatoid | 55 | 2026 | 346 | 10.830 |
Why?
|
| Antirheumatic Agents | 44 | 2026 | 227 | 8.770 |
Why?
|
| Rheumatic Diseases | 15 | 2025 | 42 | 4.410 |
Why?
|
| Rheumatology | 17 | 2025 | 70 | 4.400 |
Why?
|
| Nephrogenic Fibrosing Dermopathy | 17 | 2016 | 22 | 4.120 |
Why?
|
| Contrast Media | 16 | 2016 | 432 | 3.080 |
Why?
|
| Gadolinium | 14 | 2016 | 110 | 2.960 |
Why?
|
| Spondylarthritis | 11 | 2024 | 39 | 2.630 |
Why?
|
| Arthritis, Psoriatic | 9 | 2025 | 32 | 2.580 |
Why?
|
| Spondylitis, Ankylosing | 9 | 2024 | 24 | 2.430 |
Why?
|
| Antibodies, Monoclonal | 20 | 2025 | 876 | 2.300 |
Why?
|
| Infliximab | 12 | 2022 | 50 | 2.220 |
Why?
|
| Methotrexate | 15 | 2021 | 80 | 1.990 |
Why?
|
| Humans | 156 | 2026 | 65632 | 1.420 |
Why?
|
| Adalimumab | 9 | 2023 | 30 | 1.400 |
Why?
|
| Kidney Failure, Chronic | 12 | 2010 | 197 | 1.280 |
Why?
|
| Double-Blind Method | 22 | 2026 | 745 | 1.240 |
Why?
|
| Drug Approval | 6 | 2020 | 28 | 1.190 |
Why?
|
| United States Food and Drug Administration | 3 | 2024 | 92 | 0.990 |
Why?
|
| Skin Diseases | 6 | 2016 | 80 | 0.990 |
Why?
|
| Joints | 4 | 2017 | 33 | 0.980 |
Why?
|
| Tumor Necrosis Factor-alpha | 13 | 2025 | 604 | 0.980 |
Why?
|
| Skin | 10 | 2016 | 436 | 0.900 |
Why?
|
| Gadolinium DTPA | 4 | 2016 | 84 | 0.890 |
Why?
|
| Treatment Outcome | 27 | 2025 | 5818 | 0.850 |
Why?
|
| Fibrosis | 8 | 2013 | 172 | 0.810 |
Why?
|
| Antibodies, Monoclonal, Humanized | 9 | 2025 | 253 | 0.800 |
Why?
|
| Male | 66 | 2026 | 31281 | 0.760 |
Why?
|
| Middle Aged | 51 | 2026 | 18431 | 0.750 |
Why?
|
| Therapeutic Equivalency | 5 | 2022 | 16 | 0.750 |
Why?
|
| Crohn Disease | 1 | 2023 | 106 | 0.730 |
Why?
|
| Severity of Illness Index | 17 | 2025 | 1567 | 0.720 |
Why?
|
| Biological Therapy | 4 | 2019 | 16 | 0.720 |
Why?
|
| Arthritis | 2 | 2020 | 52 | 0.700 |
Why?
|
| Vasculitis | 4 | 2024 | 49 | 0.680 |
Why?
|
| Female | 63 | 2026 | 34294 | 0.680 |
Why?
|
| Adult | 44 | 2026 | 17507 | 0.670 |
Why?
|
| Azetidines | 1 | 2020 | 8 | 0.650 |
Why?
|
| Hematologic Agents | 1 | 2020 | 3 | 0.640 |
Why?
|
| Filgrastim | 1 | 2020 | 8 | 0.640 |
Why?
|
| Bone and Bones | 3 | 2016 | 152 | 0.630 |
Why?
|
| Magnetic Resonance Imaging | 10 | 2019 | 2252 | 0.590 |
Why?
|
| Scleroderma, Systemic | 3 | 2016 | 20 | 0.590 |
Why?
|
| Patient Care Management | 1 | 2019 | 30 | 0.590 |
Why?
|
| Prostatic Neoplasms | 6 | 2022 | 501 | 0.580 |
Why?
|
| Practice Guidelines as Topic | 6 | 2024 | 741 | 0.580 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2024 | 202 | 0.560 |
Why?
|
| Kidney Diseases | 3 | 2011 | 178 | 0.560 |
Why?
|
| Academic Medical Centers | 1 | 2020 | 309 | 0.550 |
Why?
|
| Spondylarthropathies | 2 | 2019 | 4 | 0.540 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 170 | 0.540 |
Why?
|
| Amyloidosis | 9 | 2008 | 70 | 0.530 |
Why?
|
| Organometallic Compounds | 3 | 2016 | 71 | 0.510 |
Why?
|
| Acquired Hyperostosis Syndrome | 1 | 2016 | 2 | 0.500 |
Why?
|
| United States | 11 | 2024 | 8165 | 0.500 |
Why?
|
| Renal Insufficiency, Chronic | 4 | 2014 | 146 | 0.490 |
Why?
|
| Biological Products | 3 | 2024 | 93 | 0.490 |
Why?
|
| Osteoarthritis | 3 | 2024 | 146 | 0.480 |
Why?
|
| C-Reactive Protein | 5 | 2019 | 169 | 0.480 |
Why?
|
| Acute-Phase Proteins | 2 | 2014 | 35 | 0.480 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2020 | 546 | 0.470 |
Why?
|
| Immunologic Factors | 4 | 2015 | 108 | 0.470 |
Why?
|
| Exercise | 2 | 2020 | 970 | 0.460 |
Why?
|
| Aged | 30 | 2026 | 15084 | 0.460 |
Why?
|
| Surveys and Questionnaires | 5 | 2022 | 2788 | 0.450 |
Why?
|
| Molecular Targeted Therapy | 4 | 2025 | 129 | 0.450 |
Why?
|
| beta 2-Microglobulin | 10 | 2001 | 49 | 0.440 |
Why?
|
| Macrophages | 4 | 2014 | 1041 | 0.430 |
Why?
|
| Meglumine | 2 | 2016 | 21 | 0.420 |
Why?
|
| Peritoneum | 1 | 2014 | 31 | 0.420 |
Why?
|
| Hypophosphatemia | 1 | 2014 | 7 | 0.420 |
Why?
|
| Cryoglobulinemia | 2 | 2005 | 3 | 0.420 |
Why?
|
| Blood Sedimentation | 1 | 2014 | 7 | 0.410 |
Why?
|
| Peritonitis | 1 | 2014 | 43 | 0.410 |
Why?
|
| Immunoglobulin G | 4 | 2018 | 473 | 0.400 |
Why?
|
| Polychondritis, Relapsing | 1 | 2013 | 3 | 0.390 |
Why?
|
| Remission Induction | 8 | 2019 | 149 | 0.390 |
Why?
|
| Gastrointestinal Diseases | 2 | 2013 | 69 | 0.390 |
Why?
|
| Quality of Life | 7 | 2025 | 1264 | 0.390 |
Why?
|
| Injections, Subcutaneous | 6 | 2021 | 70 | 0.380 |
Why?
|
| Rare Diseases | 1 | 2013 | 45 | 0.380 |
Why?
|
| Anti-Citrullinated Protein Antibodies | 2 | 2026 | 7 | 0.370 |
Why?
|
| Interleukin-1beta | 1 | 2014 | 274 | 0.370 |
Why?
|
| Global Health | 1 | 2013 | 181 | 0.360 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2013 | 93 | 0.360 |
Why?
|
| Risk Factors | 11 | 2018 | 5466 | 0.360 |
Why?
|
| Piperazines | 2 | 2011 | 86 | 0.350 |
Why?
|
| Renal Insufficiency | 2 | 2009 | 68 | 0.350 |
Why?
|
| Drug Therapy, Combination | 8 | 2021 | 463 | 0.350 |
Why?
|
| Pyrimidines | 2 | 2011 | 144 | 0.340 |
Why?
|
| Drugs, Generic | 1 | 2011 | 20 | 0.340 |
Why?
|
| Glycation End Products, Advanced | 5 | 2003 | 19 | 0.330 |
Why?
|
| Kidney | 4 | 2016 | 458 | 0.330 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2011 | 198 | 0.330 |
Why?
|
| Neoplasms | 3 | 2022 | 1376 | 0.330 |
Why?
|
| Cohort Studies | 7 | 2025 | 2639 | 0.320 |
Why?
|
| Bursitis | 1 | 2010 | 18 | 0.320 |
Why?
|
| Area Under Curve | 3 | 2021 | 149 | 0.320 |
Why?
|
| Renal Dialysis | 6 | 2000 | 191 | 0.320 |
Why?
|
| Inflammasomes | 1 | 2014 | 352 | 0.320 |
Why?
|
| Diabetes Complications | 1 | 2010 | 106 | 0.310 |
Why?
|
| Comorbidity | 5 | 2013 | 1120 | 0.310 |
Why?
|
| Autopsy | 1 | 2009 | 56 | 0.310 |
Why?
|
| Carrier Proteins | 1 | 2014 | 718 | 0.300 |
Why?
|
| Societies, Medical | 5 | 2024 | 400 | 0.300 |
Why?
|
| Cost Savings | 2 | 2020 | 60 | 0.300 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2022 | 808 | 0.290 |
Why?
|
| Medical Records Systems, Computerized | 1 | 2009 | 62 | 0.290 |
Why?
|
| Software | 2 | 2009 | 401 | 0.280 |
Why?
|
| Lupus Erythematosus, Systemic | 3 | 2025 | 183 | 0.280 |
Why?
|
| Terminology as Topic | 6 | 2016 | 145 | 0.280 |
Why?
|
| Disease Progression | 7 | 2018 | 1225 | 0.280 |
Why?
|
| Prostate | 3 | 2022 | 124 | 0.270 |
Why?
|
| Fatigue | 2 | 2025 | 114 | 0.270 |
Why?
|
| Diagnosis, Differential | 7 | 2016 | 992 | 0.270 |
Why?
|
| Teriparatide | 2 | 2018 | 7 | 0.270 |
Why?
|
| Pulmonary Fibrosis | 1 | 2008 | 81 | 0.260 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2019 | 858 | 0.260 |
Why?
|
| Tomography, X-Ray Computed | 7 | 2022 | 1660 | 0.250 |
Why?
|
| Precision Medicine | 2 | 2025 | 134 | 0.250 |
Why?
|
| Back Pain | 3 | 2022 | 49 | 0.250 |
Why?
|
| Radiography | 4 | 2017 | 558 | 0.240 |
Why?
|
| Receptors, Immunologic | 5 | 2003 | 179 | 0.240 |
Why?
|
| Temporal Arteries | 1 | 2006 | 5 | 0.240 |
Why?
|
| Giant Cell Arteritis | 1 | 2006 | 6 | 0.240 |
Why?
|
| Hydroxychloroquine | 1 | 2026 | 19 | 0.240 |
Why?
|
| Prevalence | 5 | 2013 | 1453 | 0.230 |
Why?
|
| Qualitative Research | 5 | 2022 | 762 | 0.230 |
Why?
|
| Clinical Trials as Topic | 2 | 2024 | 462 | 0.230 |
Why?
|
| Databases, Factual | 4 | 2024 | 888 | 0.230 |
Why?
|
| Glomerulonephritis, Membranoproliferative | 1 | 2005 | 4 | 0.230 |
Why?
|
| Cardiovascular Diseases | 1 | 2013 | 872 | 0.230 |
Why?
|
| Antibodies, Antinuclear | 2 | 2018 | 41 | 0.230 |
Why?
|
| Synovial Membrane | 1 | 2025 | 21 | 0.220 |
Why?
|
| Interleukin-1 | 3 | 2004 | 154 | 0.220 |
Why?
|
| Attitude of Health Personnel | 2 | 2009 | 631 | 0.220 |
Why?
|
| Internationality | 2 | 2015 | 46 | 0.210 |
Why?
|
| Viral Load | 1 | 2025 | 230 | 0.210 |
Why?
|
| Monocytes | 4 | 2001 | 361 | 0.210 |
Why?
|
| Anti-HIV Agents | 1 | 2025 | 139 | 0.210 |
Why?
|
| Healthy Volunteers | 2 | 2021 | 72 | 0.210 |
Why?
|
| Cytokines | 3 | 2025 | 964 | 0.210 |
Why?
|
| Drug Industry | 3 | 2018 | 41 | 0.210 |
Why?
|
| Biomedical Research | 2 | 2017 | 263 | 0.200 |
Why?
|
| Hospitals, General | 1 | 2023 | 18 | 0.200 |
Why?
|
| Rituximab | 3 | 2017 | 89 | 0.200 |
Why?
|
| Massachusetts | 3 | 2023 | 2154 | 0.190 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2025 | 142 | 0.190 |
Why?
|
| Physicians, Primary Care | 2 | 2021 | 79 | 0.190 |
Why?
|
| Drug Costs | 2 | 2020 | 55 | 0.190 |
Why?
|
| Gout | 2 | 2016 | 48 | 0.190 |
Why?
|
| Ultrasonography | 2 | 2016 | 491 | 0.180 |
Why?
|
| Prostatic Hyperplasia | 1 | 2022 | 35 | 0.180 |
Why?
|
| Inflammation | 2 | 2021 | 1195 | 0.180 |
Why?
|
| Europe | 5 | 2015 | 199 | 0.180 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2002 | 38 | 0.180 |
Why?
|
| Psoriasis | 1 | 2022 | 59 | 0.180 |
Why?
|
| Dopamine | 1 | 2022 | 108 | 0.180 |
Why?
|
| Patient Care Planning | 2 | 2019 | 85 | 0.170 |
Why?
|
| Drug Substitution | 3 | 2025 | 40 | 0.170 |
Why?
|
| Graft vs Host Disease | 1 | 2022 | 113 | 0.170 |
Why?
|
| Retrospective Studies | 8 | 2025 | 6946 | 0.170 |
Why?
|
| Depression, Postpartum | 1 | 2023 | 121 | 0.170 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2019 | 770 | 0.170 |
Why?
|
| Hyperpigmentation | 2 | 2012 | 8 | 0.160 |
Why?
|
| Janus Kinase 1 | 1 | 2020 | 17 | 0.160 |
Why?
|
| Janus Kinase 2 | 1 | 2020 | 21 | 0.160 |
Why?
|
| Purines | 1 | 2020 | 43 | 0.160 |
Why?
|
| Biomarkers | 5 | 2025 | 1487 | 0.160 |
Why?
|
| Philadelphia | 1 | 2020 | 24 | 0.160 |
Why?
|
| Medicare Part B | 1 | 2020 | 11 | 0.160 |
Why?
|
| Hepatitis C | 1 | 2002 | 144 | 0.160 |
Why?
|
| Fatal Outcome | 3 | 2009 | 122 | 0.160 |
Why?
|
| Synovial Fluid | 2 | 1991 | 29 | 0.160 |
Why?
|
| Attitude | 1 | 2020 | 102 | 0.160 |
Why?
|
| European Union | 1 | 2020 | 11 | 0.160 |
Why?
|
| Reimbursement Mechanisms | 1 | 2020 | 41 | 0.160 |
Why?
|
| Gastroenterology | 1 | 2020 | 29 | 0.160 |
Why?
|
| Republic of Korea | 1 | 2021 | 209 | 0.160 |
Why?
|
| Legislation, Drug | 1 | 2020 | 22 | 0.150 |
Why?
|
| Pyrazoles | 1 | 2020 | 88 | 0.150 |
Why?
|
| Personality Disorders | 1 | 1999 | 20 | 0.150 |
Why?
|
| Iatrogenic Disease | 1 | 2000 | 58 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 58 | 0.150 |
Why?
|
| Benzamides | 2 | 2011 | 69 | 0.150 |
Why?
|
| Observational Studies as Topic | 1 | 2020 | 72 | 0.150 |
Why?
|
| Disability Evaluation | 2 | 2012 | 216 | 0.150 |
Why?
|
| Patient Acuity | 1 | 2019 | 19 | 0.150 |
Why?
|
| Sacroiliitis | 1 | 2019 | 1 | 0.150 |
Why?
|
| Case-Control Studies | 4 | 2018 | 1144 | 0.150 |
Why?
|
| Infusions, Intravenous | 1 | 2020 | 193 | 0.150 |
Why?
|
| Certolizumab Pegol | 1 | 2019 | 2 | 0.150 |
Why?
|
| Sulfonamides | 1 | 2020 | 133 | 0.150 |
Why?
|
| Patient Participation | 2 | 2019 | 239 | 0.150 |
Why?
|
| Biopsy | 4 | 2011 | 460 | 0.150 |
Why?
|
| Risk Assessment | 3 | 2019 | 2113 | 0.150 |
Why?
|
| Lyme Disease | 2 | 1993 | 123 | 0.150 |
Why?
|
| Pain | 4 | 2024 | 400 | 0.150 |
Why?
|
| Aged, 80 and over | 7 | 2018 | 5653 | 0.150 |
Why?
|
| Evidence-Based Medicine | 3 | 2017 | 464 | 0.150 |
Why?
|
| Reproducibility of Results | 4 | 2022 | 1715 | 0.140 |
Why?
|
| Prospective Studies | 3 | 2025 | 3328 | 0.140 |
Why?
|
| Polyethylene Glycols | 1 | 2020 | 172 | 0.140 |
Why?
|
| Data Mining | 1 | 2019 | 38 | 0.140 |
Why?
|
| Animals | 11 | 2022 | 21450 | 0.140 |
Why?
|
| Consensus | 2 | 2017 | 177 | 0.140 |
Why?
|
| HIV Infections | 1 | 2025 | 958 | 0.140 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 318 | 0.140 |
Why?
|
| Medical Informatics | 1 | 2019 | 72 | 0.140 |
Why?
|
| Glucocorticoids | 2 | 2013 | 190 | 0.140 |
Why?
|
| Guideline Adherence | 3 | 2024 | 310 | 0.140 |
Why?
|
| Motivation | 1 | 2020 | 298 | 0.130 |
Why?
|
| Bone Diseases, Metabolic | 1 | 2017 | 20 | 0.130 |
Why?
|
| Pain Measurement | 2 | 2025 | 344 | 0.130 |
Why?
|
| DNA Copy Number Variations | 1 | 2017 | 73 | 0.130 |
Why?
|
| Time Factors | 9 | 2025 | 3776 | 0.130 |
Why?
|
| Bipolar Disorder | 1 | 1999 | 249 | 0.130 |
Why?
|
| Cigarette Smoking | 1 | 2018 | 56 | 0.130 |
Why?
|
| Lymphoma | 1 | 2018 | 101 | 0.130 |
Why?
|
| Health Services Needs and Demand | 1 | 2019 | 220 | 0.130 |
Why?
|
| Bone Density Conservation Agents | 1 | 2017 | 45 | 0.130 |
Why?
|
| Delayed Diagnosis | 3 | 2022 | 46 | 0.130 |
Why?
|
| Review Literature as Topic | 2 | 2016 | 40 | 0.130 |
Why?
|
| Snail Family Transcription Factors | 1 | 2016 | 29 | 0.130 |
Why?
|
| Radionuclide Imaging | 1 | 2016 | 129 | 0.120 |
Why?
|
| Bone Density | 1 | 2017 | 142 | 0.120 |
Why?
|
| Social Media | 1 | 2019 | 129 | 0.120 |
Why?
|
| Alcoholism | 1 | 1999 | 329 | 0.120 |
Why?
|
| Uric Acid | 1 | 2016 | 47 | 0.120 |
Why?
|
| Hand Bones | 1 | 2016 | 2 | 0.120 |
Why?
|
| Positron Emission Tomography Computed Tomography | 1 | 2016 | 63 | 0.120 |
Why?
|
| Heterocyclic Compounds | 1 | 2016 | 12 | 0.120 |
Why?
|
| Education, Medical, Graduate | 1 | 2019 | 348 | 0.120 |
Why?
|
| Sequence Analysis, DNA | 1 | 2017 | 417 | 0.120 |
Why?
|
| Physicians | 1 | 2021 | 486 | 0.120 |
Why?
|
| Drug Design | 1 | 2017 | 138 | 0.120 |
Why?
|
| Hedgehog Proteins | 1 | 2016 | 116 | 0.120 |
Why?
|
| Young Adult | 3 | 2024 | 4855 | 0.120 |
Why?
|
| Monocarboxylic Acid Transporters | 1 | 2015 | 12 | 0.120 |
Why?
|
| Hand Joints | 1 | 2016 | 23 | 0.110 |
Why?
|
| Mass Screening | 1 | 2021 | 700 | 0.110 |
Why?
|
| International Agencies | 1 | 2015 | 7 | 0.110 |
Why?
|
| Predictive Value of Tests | 2 | 2009 | 1116 | 0.110 |
Why?
|
| Clonal Evolution | 1 | 2015 | 6 | 0.110 |
Why?
|
| RNA, Long Noncoding | 1 | 2017 | 170 | 0.110 |
Why?
|
| Biological Availability | 1 | 2016 | 210 | 0.110 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 2015 | 33 | 0.110 |
Why?
|
| Bone Resorption | 2 | 2016 | 46 | 0.110 |
Why?
|
| China | 2 | 2015 | 180 | 0.110 |
Why?
|
| Biomarkers, Tumor | 1 | 2018 | 526 | 0.110 |
Why?
|
| Creatinine | 3 | 2011 | 136 | 0.110 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 198 | 0.110 |
Why?
|
| Advisory Committees | 1 | 2015 | 111 | 0.110 |
Why?
|
| Health Status | 2 | 2021 | 448 | 0.100 |
Why?
|
| Fibronectins | 2 | 1991 | 44 | 0.100 |
Why?
|
| Clinical Competence | 1 | 2019 | 732 | 0.100 |
Why?
|
| CARD Signaling Adaptor Proteins | 1 | 2014 | 66 | 0.100 |
Why?
|
| Drug Monitoring | 1 | 2015 | 203 | 0.100 |
Why?
|
| Inflammation Mediators | 2 | 2013 | 179 | 0.100 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2014 | 152 | 0.100 |
Why?
|
| Caveolin 1 | 1 | 2013 | 10 | 0.100 |
Why?
|
| Ear Cartilage | 1 | 2013 | 9 | 0.100 |
Why?
|
| Scleroderma, Diffuse | 1 | 2012 | 2 | 0.100 |
Why?
|
| Self Report | 1 | 2015 | 393 | 0.100 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2013 | 61 | 0.100 |
Why?
|
| Raynaud Disease | 1 | 2012 | 4 | 0.100 |
Why?
|
| Quality Assurance, Health Care | 1 | 2015 | 253 | 0.100 |
Why?
|
| Osteoporosis | 1 | 2013 | 113 | 0.090 |
Why?
|
| Contracture | 1 | 2012 | 9 | 0.090 |
Why?
|
| Dexamethasone | 1 | 1994 | 214 | 0.090 |
Why?
|
| Imatinib Mesylate | 2 | 2011 | 34 | 0.090 |
Why?
|
| Hemoglobins | 1 | 2013 | 136 | 0.090 |
Why?
|
| Hydrocortisone | 1 | 1994 | 192 | 0.090 |
Why?
|
| Canada | 1 | 2012 | 157 | 0.090 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2015 | 588 | 0.090 |
Why?
|
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2014 | 263 | 0.090 |
Why?
|
| Congresses as Topic | 2 | 2025 | 78 | 0.090 |
Why?
|
| Epigenesis, Genetic | 1 | 2015 | 408 | 0.090 |
Why?
|
| Lung Diseases | 1 | 2013 | 183 | 0.090 |
Why?
|
| Shoulder | 2 | 2010 | 29 | 0.090 |
Why?
|
| North America | 4 | 2015 | 114 | 0.090 |
Why?
|
| Quality Indicators, Health Care | 1 | 2015 | 348 | 0.090 |
Why?
|
| Arthrography | 1 | 2011 | 7 | 0.090 |
Why?
|
| Opsonin Proteins | 1 | 1991 | 32 | 0.090 |
Why?
|
| Health Care Surveys | 2 | 2009 | 288 | 0.080 |
Why?
|
| Health Services Accessibility | 1 | 2017 | 603 | 0.080 |
Why?
|
| Dermis | 1 | 2011 | 22 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2013 | 381 | 0.080 |
Why?
|
| Shoulder Impingement Syndrome | 1 | 2010 | 2 | 0.080 |
Why?
|
| Hearing Loss, Sensorineural | 1 | 2011 | 34 | 0.080 |
Why?
|
| Immunohistochemistry | 4 | 2018 | 897 | 0.080 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2013 | 517 | 0.080 |
Why?
|
| Muscular Diseases | 2 | 2006 | 51 | 0.080 |
Why?
|
| Risk Reduction Behavior | 1 | 2011 | 122 | 0.080 |
Why?
|
| International Cooperation | 4 | 2010 | 87 | 0.080 |
Why?
|
| Adolescent | 4 | 2016 | 6348 | 0.080 |
Why?
|
| Range of Motion, Articular | 1 | 2010 | 116 | 0.080 |
Why?
|
| Cost of Illness | 2 | 2022 | 169 | 0.080 |
Why?
|
| Edema | 2 | 2009 | 42 | 0.080 |
Why?
|
| Cross-Sectional Studies | 2 | 2015 | 2729 | 0.080 |
Why?
|
| Recovery of Function | 1 | 2011 | 292 | 0.080 |
Why?
|
| Registries | 1 | 2014 | 933 | 0.080 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2011 | 142 | 0.080 |
Why?
|
| Serum Amyloid A Protein | 1 | 2009 | 7 | 0.070 |
Why?
|
| E-Selectin | 1 | 2009 | 19 | 0.070 |
Why?
|
| Pilot Projects | 1 | 2013 | 1026 | 0.070 |
Why?
|
| Medical Informatics Applications | 1 | 2009 | 13 | 0.070 |
Why?
|
| Clone Cells | 2 | 2022 | 111 | 0.070 |
Why?
|
| Thromboembolism | 1 | 2009 | 74 | 0.070 |
Why?
|
| Interleukin-18 | 1 | 2009 | 75 | 0.070 |
Why?
|
| Mice, Knockout | 1 | 2014 | 2168 | 0.070 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2009 | 65 | 0.070 |
Why?
|
| Pregnancy | 3 | 2023 | 2392 | 0.070 |
Why?
|
| Receptors, Cell Surface | 1 | 1991 | 432 | 0.070 |
Why?
|
| Drug Eruptions | 1 | 2008 | 17 | 0.070 |
Why?
|
| Cause of Death | 1 | 2009 | 221 | 0.070 |
Why?
|
| Disease Models, Animal | 2 | 2014 | 2319 | 0.070 |
Why?
|
| Chronic Kidney Disease-Mineral and Bone Disorder | 1 | 2008 | 5 | 0.070 |
Why?
|
| Chondrocalcinosis | 1 | 2008 | 3 | 0.070 |
Why?
|
| Uremia | 1 | 2008 | 9 | 0.070 |
Why?
|
| Eosinophilia | 1 | 1988 | 37 | 0.070 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2008 | 28 | 0.070 |
Why?
|
| Receptor for Advanced Glycation End Products | 3 | 2003 | 21 | 0.070 |
Why?
|
| Joint Diseases | 1 | 2008 | 22 | 0.070 |
Why?
|
| Patient Satisfaction | 1 | 2011 | 442 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2013 | 644 | 0.070 |
Why?
|
| Insulin Resistance | 1 | 2011 | 415 | 0.070 |
Why?
|
| Proportional Hazards Models | 1 | 2009 | 746 | 0.060 |
Why?
|
| Syndrome | 1 | 2007 | 180 | 0.060 |
Why?
|
| Acanthamoeba | 1 | 2006 | 1 | 0.060 |
Why?
|
| Amebiasis | 1 | 2006 | 1 | 0.060 |
Why?
|
| Drug Resistance | 1 | 2008 | 158 | 0.060 |
Why?
|
| Shock, Septic | 1 | 2008 | 89 | 0.060 |
Why?
|
| Granuloma | 1 | 2006 | 43 | 0.060 |
Why?
|
| Mice, Inbred C57BL | 1 | 2014 | 3500 | 0.060 |
Why?
|
| Pneumonia | 1 | 2009 | 295 | 0.060 |
Why?
|
| Granulomatosis with Polyangiitis | 1 | 2006 | 13 | 0.060 |
Why?
|
| Acute-Phase Reaction | 3 | 2010 | 18 | 0.060 |
Why?
|
| Encephalitis | 1 | 2006 | 39 | 0.060 |
Why?
|
| Synovitis | 3 | 2010 | 30 | 0.060 |
Why?
|
| Peptides, Cyclic | 1 | 2026 | 23 | 0.060 |
Why?
|
| Pharyngitis | 1 | 2006 | 14 | 0.060 |
Why?
|
| Early Diagnosis | 3 | 2010 | 95 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 2 | 2011 | 733 | 0.060 |
Why?
|
| Rocky Mountain Spotted Fever | 1 | 2005 | 1 | 0.060 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2018 | 316 | 0.060 |
Why?
|
| Mice | 3 | 2022 | 11172 | 0.060 |
Why?
|
| Myocardium | 1 | 2008 | 302 | 0.060 |
Why?
|
| Knee Joint | 1 | 2008 | 312 | 0.060 |
Why?
|
| Autoantibodies | 2 | 2018 | 185 | 0.060 |
Why?
|
| Mental Disorders | 1 | 2013 | 825 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2009 | 2496 | 0.060 |
Why?
|
| Exanthema | 1 | 2005 | 27 | 0.060 |
Why?
|
| Prednisone | 1 | 2005 | 83 | 0.060 |
Why?
|
| Logistic Models | 2 | 2019 | 1273 | 0.060 |
Why?
|
| Dyspnea | 1 | 2006 | 120 | 0.060 |
Why?
|
| Pragmatic Clinical Trials as Topic | 1 | 2025 | 37 | 0.060 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2025 | 49 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 1 | 2025 | 160 | 0.050 |
Why?
|
| Interleukin-23 | 1 | 2024 | 18 | 0.050 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2004 | 64 | 0.050 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 214 | 0.050 |
Why?
|
| Anorexia Nervosa | 1 | 1983 | 16 | 0.050 |
Why?
|
| Research Design | 2 | 2017 | 590 | 0.050 |
Why?
|
| Rabbits | 1 | 2004 | 342 | 0.050 |
Why?
|
| Models, Animal | 1 | 2004 | 242 | 0.050 |
Why?
|
| Collagen | 3 | 1998 | 135 | 0.050 |
Why?
|
| Time-to-Treatment | 1 | 2024 | 133 | 0.050 |
Why?
|
| Sleep | 1 | 2025 | 245 | 0.050 |
Why?
|
| Nucleotides | 1 | 2022 | 48 | 0.050 |
Why?
|
| Epidemiologic Methods | 2 | 2014 | 67 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 3 | 1 | 2002 | 12 | 0.050 |
Why?
|
| Glucans | 2 | 1994 | 66 | 0.050 |
Why?
|
| Ion Channels | 1 | 2022 | 92 | 0.040 |
Why?
|
| Trisomy | 1 | 2002 | 22 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2002 | 104 | 0.040 |
Why?
|
| Etanercept | 2 | 2013 | 33 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor | 2 | 2013 | 64 | 0.040 |
Why?
|
| Syringes | 1 | 2021 | 12 | 0.040 |
Why?
|
| Sports Medicine | 1 | 2021 | 28 | 0.040 |
Why?
|
| General Practitioners | 1 | 2021 | 14 | 0.040 |
Why?
|
| Phagocytosis | 2 | 1994 | 257 | 0.040 |
Why?
|
| Sex Factors | 1 | 2024 | 995 | 0.040 |
Why?
|
| Longitudinal Studies | 1 | 2025 | 1288 | 0.040 |
Why?
|
| Chronic Disease | 2 | 2016 | 744 | 0.040 |
Why?
|
| Triazoles | 1 | 2021 | 63 | 0.040 |
Why?
|
| Phenotype | 2 | 2015 | 1235 | 0.040 |
Why?
|
| Psychometrics | 1 | 2022 | 396 | 0.040 |
Why?
|
| Hypertension | 1 | 2005 | 616 | 0.040 |
Why?
|
| Nutrition Surveys | 1 | 2021 | 149 | 0.040 |
Why?
|
| Pyridines | 1 | 2021 | 120 | 0.040 |
Why?
|
| Information Technology | 1 | 2019 | 3 | 0.040 |
Why?
|
| Information Management | 1 | 2019 | 12 | 0.040 |
Why?
|
| Expert Testimony | 1 | 2019 | 28 | 0.040 |
Why?
|
| United Kingdom | 1 | 2019 | 86 | 0.040 |
Why?
|
| Psychiatric Status Rating Scales | 1 | 1999 | 382 | 0.040 |
Why?
|
| Inservice Training | 1 | 2019 | 85 | 0.040 |
Why?
|
| Neoplasm Grading | 1 | 2018 | 101 | 0.030 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2018 | 21 | 0.030 |
Why?
|
| Image-Guided Biopsy | 1 | 2018 | 50 | 0.030 |
Why?
|
| Brain | 1 | 2006 | 1618 | 0.030 |
Why?
|
| Guanidines | 1 | 1998 | 13 | 0.030 |
Why?
|
| Denmark | 1 | 2018 | 19 | 0.030 |
Why?
|
| Mutation | 2 | 2018 | 2670 | 0.030 |
Why?
|
| BRCA2 Protein | 1 | 2018 | 20 | 0.030 |
Why?
|
| Sweden | 1 | 2018 | 65 | 0.030 |
Why?
|
| Oncogenes | 1 | 2018 | 70 | 0.030 |
Why?
|
| Lymphoma, Follicular | 1 | 2018 | 18 | 0.030 |
Why?
|
| Cognition | 1 | 2022 | 511 | 0.030 |
Why?
|
| Immunoglobulin M | 1 | 2018 | 116 | 0.030 |
Why?
|
| Ulna | 1 | 2017 | 5 | 0.030 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2018 | 47 | 0.030 |
Why?
|
| Hodgkin Disease | 1 | 2018 | 54 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2018 | 54 | 0.030 |
Why?
|
| Metacarpophalangeal Joint | 1 | 2017 | 10 | 0.030 |
Why?
|
| Radius | 1 | 2017 | 20 | 0.030 |
Why?
|
| Electronic Health Records | 1 | 2021 | 398 | 0.030 |
Why?
|
| Sequence Deletion | 1 | 2017 | 115 | 0.030 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2018 | 67 | 0.030 |
Why?
|
| Medication Therapy Management | 1 | 2017 | 18 | 0.030 |
Why?
|
| Infant | 1 | 2022 | 1710 | 0.030 |
Why?
|
| Cicatrix, Hypertrophic | 1 | 2016 | 1 | 0.030 |
Why?
|
| Immunoglobulin A | 1 | 2018 | 102 | 0.030 |
Why?
|
| Patched Receptors | 1 | 2016 | 10 | 0.030 |
Why?
|
| Keloid | 1 | 2016 | 3 | 0.030 |
Why?
|
| Aging | 1 | 2003 | 775 | 0.030 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2016 | 36 | 0.030 |
Why?
|
| Prostatectomy | 1 | 2017 | 104 | 0.030 |
Why?
|
| Membrane Proteins | 1 | 2022 | 925 | 0.030 |
Why?
|
| Health Priorities | 1 | 2016 | 29 | 0.030 |
Why?
|
| Evaluation Studies as Topic | 1 | 1996 | 105 | 0.030 |
Why?
|
| beta Catenin | 1 | 2016 | 100 | 0.030 |
Why?
|
| Cicatrix | 1 | 2016 | 62 | 0.030 |
Why?
|
| Carpal Tunnel Syndrome | 1 | 1996 | 41 | 0.030 |
Why?
|
| Cells, Cultured | 3 | 2001 | 2189 | 0.030 |
Why?
|
| Alleles | 1 | 2017 | 455 | 0.030 |
Why?
|
| Pharmacovigilance | 1 | 2016 | 15 | 0.030 |
Why?
|
| Fibroblasts | 1 | 1998 | 423 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 1998 | 369 | 0.030 |
Why?
|
| Intention to Treat Analysis | 1 | 2015 | 21 | 0.030 |
Why?
|
| Odds Ratio | 1 | 2018 | 755 | 0.030 |
Why?
|
| Transcriptional Regulator ERG | 1 | 2015 | 9 | 0.030 |
Why?
|
| ROC Curve | 1 | 1996 | 292 | 0.030 |
Why?
|
| Medicaid | 1 | 2019 | 375 | 0.030 |
Why?
|
| Apoptosis | 1 | 2001 | 1100 | 0.030 |
Why?
|
| Guidelines as Topic | 1 | 2016 | 159 | 0.030 |
Why?
|
| Osteogenesis | 1 | 2016 | 154 | 0.030 |
Why?
|
| 5' Untranslated Regions | 1 | 2015 | 28 | 0.030 |
Why?
|
| Genome, Human | 1 | 2017 | 238 | 0.030 |
Why?
|
| Asia | 1 | 2015 | 25 | 0.030 |
Why?
|
| Medicare | 1 | 2019 | 629 | 0.030 |
Why?
|
| Needs Assessment | 1 | 2016 | 202 | 0.030 |
Why?
|
| Primary Health Care | 1 | 2021 | 725 | 0.030 |
Why?
|
| Medication Adherence | 1 | 2016 | 202 | 0.030 |
Why?
|
| Amino Acid Motifs | 1 | 2015 | 156 | 0.030 |
Why?
|
| Treatment Failure | 1 | 2015 | 208 | 0.030 |
Why?
|
| Algorithms | 2 | 2010 | 1051 | 0.030 |
Why?
|
| Curriculum | 1 | 2019 | 610 | 0.030 |
Why?
|
| Microscopy, Confocal | 1 | 2015 | 240 | 0.030 |
Why?
|
| Neoplasm Metastasis | 1 | 2015 | 223 | 0.030 |
Why?
|
| Receptors, Androgen | 1 | 2015 | 88 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 2 | 1993 | 807 | 0.030 |
Why?
|
| Activities of Daily Living | 1 | 1996 | 294 | 0.030 |
Why?
|
| Life Style | 1 | 2016 | 324 | 0.030 |
Why?
|
| Electrophoresis, Gel, Two-Dimensional | 2 | 1991 | 37 | 0.030 |
Why?
|
| Genomics | 1 | 2017 | 386 | 0.030 |
Why?
|
| Receptors, Interleukin-6 | 1 | 2014 | 15 | 0.030 |
Why?
|
| Cell Lineage | 1 | 2015 | 282 | 0.020 |
Why?
|
| Phylogeny | 1 | 2015 | 399 | 0.020 |
Why?
|
| Trans-Activators | 1 | 2015 | 321 | 0.020 |
Why?
|
| Blood Proteins | 1 | 1994 | 84 | 0.020 |
Why?
|
| Analysis of Variance | 2 | 2009 | 606 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 1996 | 1172 | 0.020 |
Why?
|
| Gene Frequency | 1 | 2013 | 124 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 296 | 0.020 |
Why?
|
| Codon | 1 | 2013 | 60 | 0.020 |
Why?
|
| Protein Biosynthesis | 1 | 2015 | 333 | 0.020 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 489 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2015 | 593 | 0.020 |
Why?
|
| Introns | 1 | 2013 | 114 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2013 | 413 | 0.020 |
Why?
|
| Bacterial Vaccines | 1 | 1993 | 79 | 0.020 |
Why?
|
| Shoulder Joint | 1 | 1992 | 33 | 0.020 |
Why?
|
| Acute Kidney Injury | 1 | 2014 | 142 | 0.020 |
Why?
|
| Bone Diseases | 1 | 1992 | 25 | 0.020 |
Why?
|
| Kinetics | 1 | 1994 | 757 | 0.020 |
Why?
|
| Anemia | 1 | 2013 | 132 | 0.020 |
Why?
|
| Cell Line | 2 | 1998 | 2029 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2016 | 703 | 0.020 |
Why?
|
| Precipitin Tests | 1 | 1991 | 77 | 0.020 |
Why?
|
| Chromatography, Affinity | 1 | 1991 | 52 | 0.020 |
Why?
|
| Molecular Weight | 1 | 1991 | 194 | 0.020 |
Why?
|
| Cell Count | 1 | 2011 | 128 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 931 | 0.020 |
Why?
|
| Clinical Chemistry Tests | 1 | 2010 | 6 | 0.020 |
Why?
|
| Decision Making, Computer-Assisted | 1 | 2010 | 12 | 0.020 |
Why?
|
| Epitopes | 1 | 1991 | 291 | 0.020 |
Why?
|
| Osteoclasts | 1 | 2010 | 53 | 0.020 |
Why?
|
| Blotting, Western | 1 | 1991 | 611 | 0.020 |
Why?
|
| Receptors, Very Late Antigen | 1 | 1989 | 1 | 0.020 |
Why?
|
| Receptors, Cytoadhesin | 1 | 1989 | 2 | 0.020 |
Why?
|
| Tissue Inhibitor of Metalloproteinase-1 | 1 | 2009 | 8 | 0.020 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1989 | 111 | 0.020 |
Why?
|
| Leg | 1 | 2009 | 87 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2013 | 735 | 0.020 |
Why?
|
| Drug Synergism | 1 | 2009 | 142 | 0.020 |
Why?
|
| Osteoblasts | 1 | 2010 | 204 | 0.020 |
Why?
|
| Antibodies | 2 | 2001 | 188 | 0.020 |
Why?
|
| Safety | 1 | 2009 | 142 | 0.020 |
Why?
|
| RNA, Small Interfering | 1 | 2015 | 986 | 0.020 |
Why?
|
| Calcium Oxalate | 1 | 2008 | 12 | 0.020 |
Why?
|
| Borrelia | 1 | 1988 | 31 | 0.020 |
Why?
|
| Bone Remodeling | 1 | 2008 | 25 | 0.020 |
Why?
|
| Decision Support Techniques | 1 | 2010 | 196 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 1988 | 233 | 0.020 |
Why?
|
| Crystallization | 1 | 2008 | 97 | 0.020 |
Why?
|
| Patient Selection | 1 | 2010 | 484 | 0.020 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 1989 | 281 | 0.020 |
Why?
|
| Antibodies, Bacterial | 1 | 1988 | 181 | 0.020 |
Why?
|
| Glycosylation | 2 | 1998 | 139 | 0.020 |
Why?
|
| Incidence | 1 | 2011 | 1432 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 1989 | 754 | 0.020 |
Why?
|
| Blood Chemical Analysis | 1 | 2006 | 20 | 0.020 |
Why?
|
| Arm | 1 | 2006 | 45 | 0.020 |
Why?
|
| Muscle Weakness | 1 | 2006 | 33 | 0.020 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2006 | 6 | 0.020 |
Why?
|
| Seizures | 1 | 2006 | 141 | 0.010 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 1989 | 642 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2015 | 3162 | 0.010 |
Why?
|
| Eosinophilia-Myalgia Syndrome | 1 | 2004 | 1 | 0.010 |
Why?
|
| Acanthocytes | 1 | 1983 | 1 | 0.010 |
Why?
|
| Bone Marrow Examination | 1 | 1983 | 8 | 0.010 |
Why?
|
| Leukopenia | 1 | 1983 | 16 | 0.010 |
Why?
|
| In Vitro Techniques | 2 | 1998 | 491 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1983 | 102 | 0.010 |
Why?
|
| Dietary Proteins | 1 | 1983 | 44 | 0.010 |
Why?
|
| Dietary Carbohydrates | 1 | 1983 | 62 | 0.010 |
Why?
|
| Child | 1 | 1993 | 4632 | 0.010 |
Why?
|
| Disease Susceptibility | 1 | 1983 | 169 | 0.010 |
Why?
|
| Complement System Proteins | 1 | 1983 | 110 | 0.010 |
Why?
|
| Staphylococcal Infections | 1 | 1983 | 131 | 0.010 |
Why?
|
| Attitude to Health | 1 | 1983 | 296 | 0.010 |
Why?
|
| Superoxides | 1 | 2001 | 73 | 0.010 |
Why?
|
| Fas Ligand Protein | 1 | 2001 | 40 | 0.010 |
Why?
|
| Intracellular Membranes | 1 | 2001 | 47 | 0.010 |
Why?
|
| Dinoprostone | 1 | 2001 | 42 | 0.010 |
Why?
|
| fas Receptor | 1 | 2001 | 56 | 0.010 |
Why?
|
| Antigens, Surface | 1 | 2001 | 199 | 0.010 |
Why?
|
| Lysosomes | 1 | 2001 | 175 | 0.010 |
Why?
|
| Propionibacterium acnes | 1 | 1979 | 6 | 0.010 |
Why?
|
| Stress, Psychological | 1 | 1983 | 475 | 0.010 |
Why?
|
| Procollagen | 1 | 1998 | 11 | 0.010 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 1979 | 138 | 0.010 |
Why?
|
| Gastric Mucosa | 1 | 1998 | 53 | 0.010 |
Why?
|
| Epidermal Growth Factor | 1 | 1998 | 49 | 0.010 |
Why?
|
| Membrane Glycoproteins | 1 | 2001 | 662 | 0.010 |
Why?
|
| Immunoblotting | 1 | 1998 | 202 | 0.010 |
Why?
|
| Spectrometry, Fluorescence | 1 | 1998 | 94 | 0.010 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 1998 | 449 | 0.010 |
Why?
|
| Intestinal Mucosa | 1 | 1998 | 253 | 0.010 |
Why?
|
| Glucose | 1 | 1998 | 478 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1979 | 1010 | 0.010 |
Why?
|
| Hip | 1 | 1992 | 7 | 0.010 |
Why?
|
| Wrist | 1 | 1992 | 39 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 1998 | 1580 | 0.010 |
Why?
|
| Spine | 1 | 1992 | 55 | 0.010 |
Why?
|
| CD3 Complex | 1 | 1989 | 63 | 0.000 |
Why?
|
| Integrin beta1 | 1 | 1989 | 32 | 0.000 |
Why?
|
| Antigens, Differentiation | 1 | 1989 | 144 | 0.000 |
Why?
|
| Extracellular Matrix | 1 | 1989 | 148 | 0.000 |
Why?
|
| Ascitic Fluid | 1 | 1979 | 12 | 0.000 |
Why?
|
| Leukemia, Experimental | 1 | 1979 | 19 | 0.000 |
Why?
|
| Mice, Inbred CBA | 1 | 1979 | 80 | 0.000 |
Why?
|
| Cell Separation | 1 | 1979 | 147 | 0.000 |
Why?
|
| Cell Adhesion | 1 | 1979 | 218 | 0.000 |
Why?
|
| Immunity, Cellular | 1 | 1979 | 170 | 0.000 |
Why?
|
| Spleen | 1 | 1979 | 476 | 0.000 |
Why?
|